ArticleJournal of pharmaceutical health care and sciences2025
Drug-induced interstitial lung disease: a pharmacovigilance study of twelve immunomodulatory and antineoplastic agents.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System.Medicine · 2026Article
- Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER.PloS one · 2026Article
- Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference.Therapeutic advances in drug safety · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced interstitial lung disease (ILD) is a potentially severe pulmonary complication associated with various immunomodulatory and antineoplastic agents. Despite increasing recognition, comparative disproportionality data across drug classes remain limited.
methodsWe conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS, 2004–2024). Twelve agents with known or suspected associations with ILD were selected. For each drug, the total number of adverse events and ILD reports were extracted. The proportional reporting ratio and reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated to assess disproportionality.
resultsMethotrexate and rituximab accounted for the highest number of ILD reports. Amiodarone hydrochloride showed the highest proportion of ILD among its adverse events (9.4%) and the strongest disproportionality signal (ROR = 7.11; 95% CI: 6.79–7.45). Elevated RORs were also noted for leflunomide (3.05), tocilizumab (1.94), pembrolizumab (1.89), and methotrexate (1.90). In contrast, TNF-α inhibitors such as adalimumab (ROR = 0.29) and etanercept (ROR = 0.34) were associated with lower disproportionality signals.
conclusionSignificant variation in ILD signal strength was observed across drug classes. Amiodarone and leflunomide showed disproportionately strong ILD signals, while TNF-α inhibitors demonstrated lower reporting frequencies. These findings underscore the need for ongoing pharmacovigilance when using agents with potential pulmonary toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.